Equities

Orchid Pharma Ltd

ORCHPHARMA:NSI

Orchid Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,400.50
  • Today's Change29.60 / 2.16%
  • Shares traded73.11k
  • 1 Year change+168.63%
  • Beta3.4160
Data delayed at least 15 minutes, as of Sep 20 2024 10:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

  • Revenue in INR (TTM)8.81bn
  • Net income in INR1.12bn
  • Incorporated1992
  • Employees872.00
  • Location
    Orchid Pharma LtdOrchid Towers313-Valluvar Kottam High, NungambakkamCHENNAI 600034IndiaIND
  • Phone+91 4 425211000
  • Fax+91 4 428211002
  • Websitehttp://www.orchidpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gufic BioSciences Ltd8.14bn863.69m40.16bn1.45k46.04--38.824.938.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
SeQuent Scientific Ltd14.27bn54.87m43.00bn1.20k807.64--55.353.010.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Innova Captab Ltd11.42bn1.06bn44.28bn--32.66--35.643.8823.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
Unichem Laboratories Ltd17.28bn-605.50m45.11bn3.19k----86.352.61-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Morepen Laboratories Ltd17.45bn1.18bn45.91bn1.62k36.26--30.682.632.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Hikal Ltd18.03bn677.82m46.42bn2.06k68.52--24.502.575.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Aarti Drugs Ltd24.23bn1.57bn47.68bn1.06k30.36--22.801.9717.0817.08263.82--------22,770,740.00--9.73--15.7834.3222.236.488.25--7.28-----6.9010.133.0713.8224.96--
Supriya Lifescience Ltd5.99bn1.35bn49.03bn448.0036.26--32.318.1916.8016.8074.42--------13,370,000.00--19.08--24.0462.7557.1222.5824.71--92.47--2.8823.7415.4732.5624.7583.79--
Aarti Pharmalabs Ltd19.50bn2.25bn59.31bn1.63k26.32--19.673.0424.8624.86215.17--------11,983,730.00--------44.20--11.55----18.55-----4.76--12.10------
Orchid Pharma Ltd8.81bn1.12bn69.06bn872.0059.49--47.137.8422.8922.89180.65--------10,101,540.00---0.9734---1.4040.6740.7412.78-2.40--6.08----23.056.4373.595.8457.79--
Sun Pharma Advanced Research Co Ltd684.05m-3.89bn70.83bn409.00------103.54-11.97-11.972.11--------1,672,501.00---61.70---119.3159.8174.49-568.24-163.40---208.33-----68.36-16.21-73.96--15.40--
Shilpa Medicare Ltd11.84bn447.57m82.93bn931.00169.78--54.187.005.005.00133.55--------12,716,850.00--2.84--3.6565.1960.083.797.03--1.56--10.769.669.44198.15-22.26-9.26--
Procter & Gamble Health Ltd11.51bn2.01bn84.68bn1.41k42.1615.7337.087.36121.01121.01693.20324.241.212.7111.45--21.21--29.28--71.29--17.46--1.90386.940.0175---6.37---12.42------
Blue Jet Healthcare Ltd6.95bn1.57bn89.01bn447.0056.53--48.6612.819.089.0840.07--------15,547,110.00--------55.54--22.65----124.37-----1.30--2.33------
F D C Ltd20.45bn3.14bn90.06bn6.66k28.79--25.334.4019.2119.21124.56--------3,070,786.00--12.05--13.7365.5561.5415.3715.85--75.15--1.098.9212.2457.3012.4516.93--
Data as of Sep 20 2024. Currency figures normalised to Orchid Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

18.03%Per cent of shares held by top holders
HolderShares% Held
quant Money Managers Ltd.as of 30 Sep 20233.23m6.36%
Invesco Asset Management (India) Pvt Ltd.as of 31 Aug 20242.45m4.84%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 20231.00m1.97%
Carnelian Asset Management & Advisors Pvt Ltd.as of 30 Sep 2023618.92k1.22%
JM Financial Asset Management Ltd.as of 31 Aug 2024531.79k1.05%
Tata Asset Management Pvt Ltd.as of 31 Aug 2024431.96k0.85%
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Aug 2024408.63k0.81%
Bajaj Finserv Asset Management Ltd.as of 31 Aug 2024303.08k0.60%
Bandhan Asset Management Co. Ltd.as of 31 Aug 2024117.77k0.23%
ITI Asset Management Ltd. (India)as of 31 Aug 202449.65k0.10%
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.